Kairos Pharma (KAPA) Stock Analysis

What Kairos Pharma does

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.

Key metrics

ETFs linked to KAPA

Broad-market and Healthcare sector ETFs an investor holding Kairos Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how KAPA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Kairos Pharma?

Kairos Pharma trades under the ticker KAPA on AMEX.

Which exchange is KAPA listed on?

KAPA is listed on AMEX.

What sector does Kairos Pharma operate in?

Kairos Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze KAPA in a portfolio?

PortView shows KAPA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.